Blepharitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Blepharitis Pipeline Drugs Market Overview

Blepharitis, an inflammation of the eyelids, occurs with symptoms including watery eyes, red eyes, itchy eyelids, and sensitivity to light. Treatment includes antibiotics, lubricating eye drops, and steroid eye drops or ointments.

The Blepharitis pipeline market research report provides an overview of the Blepharitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Blepharitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects.

Blepharitis Pipeline Drugs Market Key Targets

Some of the targets of the Blepharitis pipeline drugs market are Glucocorticoid Receptor, 16S Ribosomal RNA, 23S Ribosomal RNA, Aryl Hydrocarbon Receptor, Calcineurin, IkappaB Kinase, Janus Kinase, and Serine/Threonine Protein Kinase mTOR.

Blepharitis Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Blepharitis Pipeline Drugs Market

Some of the mechanisms of action of the Blepharitis pipeline drugs market are Glucocorticoid Receptor Agonist, 16S Ribosomal RNA Inhibitor, 23S Ribosomal RNA Inhibitor, Aryl Hydrocarbon Receptor Agonist, Calcineurin Inhibitor, IkappaB Kinase Inhibitor, Janus Kinase Inhibitor, and Serine/Threonine Protein Kinase mTOR Inhibitor.

Blepharitis Pipeline Drugs Market, by Mechanisms of Action

For more mechanisms of action insights, download a free report sample

Key Routes of Administration in the Blepharitis Pipeline Drugs Market

The routes of administration in the Blepharitis pipeline drugs market are ophthalmic, topical, intravenous, intravitreal, oral, and subconjunctival.

Blepharitis Pipeline Drugs Market, by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Blepharitis Pipeline Drugs Market

The molecule types in the Blepharitis pipeline drugs market are small molecule and biologic. Small molecule has the highest number of pipeline products.

Blepharitis Pipeline Drugs Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Blepharitis Pipeline Drugs Market Companies

Some of the key companies in the Blepharitis pipeline drugs market are Tarsus Pharmaceuticals Inc, AxeroVision Inc, Azura Ophthalmics Pty Ltd, NicOx SA, Aerie Pharmaceuticals Inc, Aperta Biosciences LLC, Formosa Pharmaceuticals Inc, Hovione FarmaCiencia SA, Merck & Co Inc, and NTC srl.

AxeroVision Inc: AxeroVision (AxeroVision) is a biotechnology company that develops therapeutics for the treatment of dry eye disease (DED) and other ophthalmic inflammatory diseases. The company is investigating AXR-159, a VLA-4 integrin antagonist for the treatment of moderate and severe dry eye disease. It is funded by Laboratories Thea and GlaxoSmithKline Plc (GSK). The company is a spin-off of GlaxoSmithKline Plc. AxeroVision is headquartered in Carlsbad, California, the US.

Blepharitis Pipeline Drugs Market, by Key Companies

To know more about key companies, download a free report sample

Market Report Overview

Scope 

This report provides:

• A snapshot of the global therapeutic landscape of Blepharitis (Ophthalmology).
• Reviews of pipeline therapeutics for Blepharitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Pipeline products are based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
• Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
• Reviews of key companies involved in Blepharitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
• Evaluation of Blepharitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• All the dormant and discontinued pipeline projects.
• Reviews of the latest news and deals related to pipeline therapeutics for Blepharitis (Ophthalmology).

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies
• Recognize emerging players with the potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
• Find and recognize significant and varied types of therapeutics under development for Blepharitis (Ophthalmology)
• Classify potential new clients or partners in the target demographic
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics
• Formulate corrective measures for pipeline projects by understanding Blepharitis (Ophthalmology) pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline